Skip to main content

Labcorp Holdings Inc.

corporate_fare Company Profile

Labcorp Holdings Inc.

LH·NYSE·Life Sciences·CIK 0000920148

Labcorp® Holdings Inc. is a global provider of innovative and comprehensive laboratory services. The company offers vital information to doctors, hospitals, pharmaceutical companies, researchers, and patients to aid decision-making. Labcorp provides insights and accelerates innovations to improve health through its diagnostics and drug development laboratory capabilities. In 2025, the company's nearly 71,000 employees served clients in approximately 100 countries and performed over 750 million tests for patients globally. Additionally, Labcorp supported more than 85% of the new drugs and therapeutic products approved by the FDA in 2025. The company leverages its strengths in science, technology, innovation, and global scale to advance healthcare. Labcorp's enterprise strategy involves providing vital information and services through leadership in science, technology, and innovation. The company is expanding its role in the healthcare market by strengthening its capabilities, pursuing strategic opportunities, and differentiating its offerings. Labcorp is focused on two near-term strategic growth opportunities across both Dx and BLS: being a partner of choice for health systems and local and regional laboratories, and leading in the development, licensing, and scaling of specialty testing. In 2025, the company signed or completed 13 collaboration transactions with health systems and local and regional laboratories. These partnerships are sought based on financial criteria, including being accretive in the first year, returning the cost of capital within three years, and providing a clear path to margin improvement.

Labcorp Holdings Inc. (NYSE:LH) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for LH at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-28, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 12 rated 8 or above. Recent SEC coverage for LH spans 8-K, 10-Q.

Recent high-impact activity:

  • Labcorp Beats Q3, Lifts 2026 Guidance, Quantifies $125M PAMA Hit
  • Labcorp Beats on Q3, Raises 2026 EPS Guidance to $18.30-$18.70
  • Labcorp Lifts FY Adjusted EPS Outlook to $18.30-$18.70
  • Labcorp to Buy Myriad's Prenatal Testing Unit in Definitive Deal
  • Labcorp Buys OPKO's BioReference Diagnostics Assets for Up to $872M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$13.95B
Net Income
$876.5M
Diluted EPS
$10.46
Op. Cash Flow
$1.64B
Free Cash Flow
$1.21B
Gross Profit
$4.01B
Operating Income
$1.38B
Cash & Equivalents
$532.3M
Total Debt
$5.58B
Debt / Equity
0.65×
Net Margin
6.3%
Shares Outstanding
82.2M sh
Source: 10-K · filed 2026-02-24 · accession 0000920148-26-000111

Short Interest & Short Volume

4.22 days to cover

FINRA reported short interest of 2,557,656 shares in LH as of the October 15, 2026 settlement, a 4.7% decrease from the prior period — about 4.2 days to cover at its recent average daily volume. On October 28, 2026, 50.8% of LH volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,557,656 shares as of October 15, 2026
Change vs prior period▼ 4.7%
Days to cover4.22 at avg daily volume of 606,767
Daily short volume (FINRA facilities)50.8% of 854,623 shares on October 28, 2026
5-day average short volume48.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with L →
$360.25
52-week range · as of 2026-10-28 $244.52 – $360.25
Market cap
$29.22B
Volume
1.8M (2.3× avg)
3-mo avg 777.4K
Live data · 2026-10-29 07:31 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed LH - Latest Insights

LH
Oct 28, 2026, 1:54 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $362.21
Real-time Price: $360.25 info
Change: -$1.95 (-0.54%) info
Market Cap: $29.216B info
LH
Oct 28, 2026, 6:57 AM EDT
Filing Type: 8-K
Importance Score:
8
Updated Oct 28, 7:10 AM ET — Labcorp expects 2026 Biopharma Laboratory Services revenue growth of 7.4%-8.4% and Diagnostics Laboratories growth of 5.5%-6.2%.
Price at Filing: $335.99
Real-time Price: $360.25 info
Change: +$24.26 (+7%) info
Market Cap: $29.216B info
LH
Oct 28, 2026, 6:50 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $330.01
Real-time Price: $360.25 info
Change: +$30.24 (+9%) info
Market Cap: $29.216B info
LH
Oct 20, 2026, 8:33 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $307.00
Real-time Price: $360.25 info
Change: +$53.25 (+17%) info
Market Cap: $29.216B info
LH
Oct 15, 2026, 11:41 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $322.40
Real-time Price: $360.25 info
Change: +$37.85 (+12%) info
Market Cap: $29.216B info
LH
Oct 15, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $318.00
Real-time Price: $360.25 info
Change: +$42.25 (+13%) info
Market Cap: $29.216B info
LH
Sep 22, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $311.54
Real-time Price: $360.25 info
Change: +$48.71 (+16%) info
Market Cap: $29.216B info
LH
Sep 22, 2026, 9:10 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $301.00
Real-time Price: $360.25 info
Change: +$59.25 (+20%) info
Market Cap: $29.216B info
LH
Sep 21, 2026, 5:13 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $305.00
Real-time Price: $360.25 info
Change: +$55.25 (+18%) info
Market Cap: $29.216B info
LH
Sep 10, 2026, 4:47 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $306.96
Real-time Price: $360.25 info
Change: +$53.29 (+17%) info
Market Cap: $29.216B info
LH
Sep 10, 2026, 9:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $322.45
Real-time Price: $360.25 info
Change: +$37.80 (+12%) info
Market Cap: $29.216B info
LH
Sep 08, 2026, 9:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $326.68
Real-time Price: $360.25 info
Change: +$33.57 (+10%) info
Market Cap: $29.216B info
LH
Aug 10, 2026, 7:29 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $315.34
Real-time Price: $360.25 info
Change: +$44.91 (+14%) info
Market Cap: $29.216B info
LH
Jul 30, 2026, 6:53 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $307.05
Real-time Price: $360.25 info
Change: +$53.20 (+17%) info
Market Cap: $29.216B info
LH
Jul 30, 2026, 6:50 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $307.05
Real-time Price: $360.25 info
Change: +$53.20 (+17%) info
Market Cap: $29.216B info
LH
Jul 28, 2026, 4:39 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $301.60
Real-time Price: $360.25 info
Change: +$58.65 (+19%) info
Market Cap: $29.216B info
LH
Jun 22, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $255.82
Real-time Price: $360.25 info
Change: +$104.43 (+41%) info
Market Cap: $29.216B info
LH
Jun 08, 2026, 12:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $263.22
Real-time Price: $360.25 info
Change: +$97.03 (+37%) info
Market Cap: $29.216B info
LH
May 29, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $262.75
Real-time Price: $360.25 info
Change: +$97.50 (+37%) info
Market Cap: $29.216B info
LH
May 04, 2026, 2:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $254.03
Real-time Price: $360.25 info
Change: +$106.22 (+42%) info
Market Cap: $29.216B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets